Skip to main content
SpringerLink
Log in

Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002; 19: 1–46

    Google Scholar 

  2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26; 347 (13): 975–82

    Article  PubMed  CAS  Google Scholar 

  3. Carithers Jr RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997 Sep; 26 (3 Suppl. 1): 83S-88S

    Article  Google Scholar 

  4. Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon c-za plus ribavirin versus interferon a-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Phannacoeconomics 2004; 22 (4): 257–65

    Article  Google Scholar 

  5. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D Immine globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228–33

    Article  PubMed  CAS  Google Scholar 

  6. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 15: 533–41

    Article  Google Scholar 

  7. Zeuzem S, Teuber G, Naumann D, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa 2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32: 835–41

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA

    Miguel Arguedas

Authors
  1. Miguel Arguedas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arguedas, M. Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. PharmacoEconomics 22, 477–478 (2004). https://doi.org/10.2165/00019053-200422070-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200422070-00005

Keywords

Search

Navigation